Drug Trial Radar · NCT00567489
IMPENDIA- PEN VS Dianeal Only Improved Metabolic Control In Diabetic CAPD and APD Patients
Last checked: Nov 20, 2026Latest source record: Jul 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
137
Actual
Start
Jan 2008
Primary completion
Jul 2011
Study completion Jul 2011
Sponsor
- Lead sponsor
- Vantive Health LLCIndustry
- Sponsor type
- Industry
- Collaborators
- Baxter Healthcare Corporation
- First posted
- Dec 5, 2007
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary Objective: To demonstrate that use of glucose sparing prescriptions (PEN vs Dianeal only) in diabetic (Type 1 and Type 2) Continuous Ambulatory Peritoneal Dialysis (CAPD) and Automated Peritoneal Dialysis (APD)patients leads to improved metabolic control as measured by the magnitude of change from the baseline value in the HbA1c levels. Secondary Objectives: To demonstrate that use of glucose-sparing PD solutions (PEN vs Dianeal only) in diabetic (Type 1 and Type 2) CAPD and APD patients leads to lower glycemic-control medication requirements, decreased incidence of severe hypoglycemic events requiring medical intervention, improved metabolic control, nutritional status, and Quality of Life. In a subgroup of patients, the impact of glucose-sparing PD solutions (PEN vs Dianeal only) on abdominal fat and left ventricular (LV) structure and function will be assessed.
Conditions
- ESRD
- Diabetes
- CAPD
- APD
Interventions
PhysionealDrug
Physioneal 40 or Physioneal 35
DianealDrug
Dianeal 1.5% Dextrose (1.30% glucose), 2.5% Dextrose (2.27% glucose), 4.5% Dextrose (3.86% glucose)
ExtranealDrug
7.5% Icodextrin
NutrinealDrug
Amino Acids 1.1%
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From the Baseline Value in HbA1c at Month 3 and 6Time frame: Baseline, Month 3, Month 6 (End of Study)
Locations
19 sites in 5 countries. Site status is shown where the registry gives one.
Kwong Wah Hospital
Kowloon, Hong Kong
Prince of Wales Hospital Chinese University of Hong Kong
Shatin, N.T., Hong Kong
Alice Ho Miu Ling Nethersole Hospital
Tai Po, N.T., Hong Kong
Moscow Clinical Hospital # 52
Moscow, Russia
Moscow Hospital n a S P Botkin
Moscow, Russia
Moscow Research n a M F Vladimirsky
Moscow, Russia
Moscow State Medical Institution: "Municipal Clinical Hospital #7 "
Moscow, Russia
St Petersburg Mariinskaya Hospital
Saint Petersburg, Russia
St Petersburg St Elizabeth Hospital
Saint Petersburg, Russia
Samara Hospital n a M I Kalinin
Samara, Russia
National University Hospital
Singapore, Singapore
Tan Tock Seng Hospital
Singapore, Singapore
Kyungpook National University Hospital
Daegu, South Korea
Yeungnam University Medical Center
Daegu, South Korea
Seoul National University Hospital
Seoul, South Korea
Yonsei University of Medical Center Severance Hospital
Seoul, South Korea
Daegu Fatima Hospital
Donggu, Deagu, South Korea
China Medical University Hospital
Taichung, Taiwan
National Taiwan University Hospital
Taipei, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.